Roche’s Giredestrant Data Could Set The Stage For A New Standard Of Care
The selective estrogen receptor degrader reduced the risk of invasive disease recurrence or death by 30% in ER-positive early stage breast cancer.
Scrip - December 10, 2025

Medtech’s Global Future Puts AI In The Driver’s Seat
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
Medtech Insight - December 10, 2025

PCPC Global Strategies Head; MAC Cosmetics & Batiste Tap Global Ambassadors; Beauty People Roundup
PCPC names Heather Helm exec VP of global strategies, replacing Francine Lamoriello who left several months ago. Separately, MAC Cosmetics announces Grammy-winning singer-songwriter Chappell Roan is its newest global brand ambassador.
HBW Insight - December 10, 2025

Autolous Looks To Expand Its CAR-T Into Crowded Lupus Field
After a solid but modest launch in acute lymphoblastic leukemia, Autolus sees an opportunity for its CAR-T in autoimmune disease, starting with lupus nephritis.
Scrip - December 10, 2025

Reckitt: Preventative Health Approach Could Save $70bn A Year In Healthcare Costs
Self-care solutions such as OTC drugs and wearables can save over 725,000 lives a year, argues a new report published by Reckitt and health insurance firm BUPA.
HBW Insight - December 10, 2025

German Giants Rise Up The Ranks In Generics Bulletin’s Top 50
Two leading German generics and biosimilars giants are the big movers at the top of our annual ranking of off-patent industry leaders. We reveal the latest developments in this year’s Generics Bulletin Top 50.
In Vivo - December 10, 2025

GSK Boosts ADC Heft Through Pact With Oxford BioTherapeutics
GSK builds up its arsenal of antibody-drug conjugates, while Oxford BioTherapeutics adds another pharma heavyweight to its expansive roster of partners.
Scrip - December 10, 2025

Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
In Vivo - December 10, 2025

Execs On The Move: November 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - December 10, 2025

Gamida Cell Goes From Strength To Strength With Another US FDA Nod
The company, which was on the verge of bankruptcy last year, has secured an expanded approval for Omisirge for severe aplastic anemia.
Scrip - December 10, 2025

Formycon Partners With Zydus To Capture US-Canada Keytruda Biosimilar Market
Formycon has again stepped closer to financial certainty with another pembrolizumab biosimilar deal. This time, it unlocked a significant opportunity for the US and Canadian markets.
Generics Bulletin - December 10, 2025

FDA Publishes PSGs For GLP-1 Giants Mounjaro, Wegovy, Victoza/Saxenda
The US FDA has delivered its December batch of product-specific guidances for generic development, marking only the second timely release of the year.
Generics Bulletin - December 10, 2025

Teva Files LAI Olanzapine With FDA, Paving Way for $2bn Schizophrenia Franchise
Teva sees olanzapine LAI as key to building a schizophrenia franchise worth up to $2bn annually, following its earlier risperidone launch.
Generics Bulletin - December 10, 2025

New Opportunities For Coordinated EU Review Of Device/IVD Investigations As EU Builds New System
Sponsors of higher risk device and diagnostic investigations are being invited to participate in a pilot that aims to reduce regulatory burden.
Medtech Insight - December 10, 2025

Indegene Exec On R&D Operations In The Age Of GenAI, One Click Submissions
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In Vivo - December 10, 2025

Podcast: Kairos Pharma’s Approach To Resensitizing Tumors
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
In Vivo - December 10, 2025

ASA Files: Prostate Supplements And Self-Tests Fall Foul Of Active Ad Monitoring System
HBW Insight extracts lessons from six ASA rulings related to ads for prostate dietary supplement and self-test products, all of which fell foul of the regulators AI-powered Active Ad Monitoring system.
HBW Insight - December 10, 2025

C&D Pulls Curtain Down On Gummy Vitamin Gambit With Sale To Piping Rock Health
Decision on vitafusion and L’il Critters business planned by end of year, but Piping Rock Health provided incentive for C&D to opt for divestiture.
HBW Insight - December 10, 2025

Phrontline’s Two-Pronged Shot At Bispecific, Dual-Payload ADCs
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Scrip - December 10, 2025

Xeltis Raises €50M To Advance Tissue-Regenerating Dialysis Access As CMS Opens Door To New Options
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025